MedTrace Logo

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

NCT02246816 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-02-18

No results posted yet for this study

Summary

MP-101 will be evaluated in this study to see if it is safe and tolerable.

Conditions

  • Short Bowel Syndrome
  • Short Gut Syndrome
  • SBS
  • Short Gut

Interventions

DRUG

0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

Sponsors & Collaborators

  • Marathon Pharmaceuticals, LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02246816 on ClinicalTrials.gov